Methods for inducing reversible stasis

• US 20050053912A1
• Filed: 06/10/2002
• Published: 03/10/2005
• Est. Priority Date: 06/11/2001
• Status: Abandoned Application

• Current Assignee: Fred Hutchinson Cancer Research Center (Fred Hutchinson Cancer Research Center|Argus Genetics|Mars)
• Original Assignee: Fred Hutchinson Cancer Research Center (Fred Hutchinson Cancer Research Center|Argus Genetics|Mars)
• Inventors: Padilla, Pamela, Roth, Mark B.
• Application Number:
  US10/480,430
• Publication Number:
  US 20050053912A1
• Time in Patent Office: Days
• US Class Current: 435/4
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0278 Physical preservation processes
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: C12N 1/04 Preserving or maintaining viable microorganisms immobilised microorganisms C12N11/00
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/5082 Supracellular entities, e.g. tissue, organisms
• CPC Class Codes: G01N 33/5088 of vertebrates

Abstract

The present invention concerns compositions and methods involving incubating biological materials under hypoxic or anoxic conditions to induce stasis or suspended animation. Methods of screening for compounds that induce stasis or compounds that increase the ability to undergo stasis are included. Such methods have ramifications for preserving biological materials as well as reducing or preventing trauma to biological materials. Also contemplated are methods for screening compounds that are active or more active under hypoxic conditions than normoxic conditions. Such methods can be used to identify antitumor compounds that would operate under hypoxic conditions in which tumor cells survive.

Claims

1. A method for cryopreserving biological material comprising:

a) first incubating the biological material under anoxic conditions for an effective amount of time for the biological material to enter stasis; and

b) then cryopreserving the biological material.

2. The method of claim 1, wherein the biological material is a cell, tissue, or organism.

3. The method of claim 2, wherein the biological material is a cell.

4. The method of claim 3, wherein the cell is a sex cell.

5. The method of claim 3, wherein the cell is comprised in an embryo.

6. The method of claim 5, wherein the embryo is a vertebrate embryo.

7. The method of claim 6, wherein the vertebrate embryo is mammalian.

8. The method of claim 2, wherein the biological material is tissue.

9. The method of claim 8, wherein the tissue is an organ.

10. The method of claim 2, wherein the biological material is an organism.

11. The method of claim 10, wherein the organism is an invertebrate.

12. The method of claim 10, wherein the organism is a vertebrate.

13. The method of claim 1, wherein the biological material is incubated under anoxic conditions for more than 30 minutes.

14. The method of claim 13, wherein the biological material is incubated under anoxic conditions for more than 1 hour.

15. The method of claim 13, wherein the biological material is incubated under anoxic conditions for more than 2 hours.

16. The method of claim 1, wherein cryopreserving the biological material comprises perfusing the biological material with a cryoprotectant and lowering the temperature of the biological material.

17. The method of claim 16, wherein the temperature is lowered to below 0°

C.

18. A method for preserving biological material comprising:

a) incubating the biological material under hypoxic conditions for an effective amount of time for the biological material to enter stasis.

19. The method of claim 18, further comprising lowering the temperature of the biological material.

20. The method of claim 18, further comprising incubating the biological material under normoxic conditions to reverse stasis.

21. The method of claim 18, wherein the biological material is incubated under conditions of less than 10% oxygen.

22. The method of claim 21, wherein the biological material is incubated under conditions of less than 5% oxygen.

23. The method of claim 18, wherein the biological material exhibits signs of trauma.

24. The method of claim 19, wherein the temperature is lowered to below 15°

C.

25. The method of claim 24, wherein the temperature is lowered to below 10°

C.

26. The method of claim 18, wherein the biological material is an organism.

27. The method of claim 18, wherein the organism is a vertebrate.

28. The method of claim 27, wherein the vertebrate is a Danio rerio embryo.

29. A method for screening for an antitumor compound comprising:

a) incubating a first anoxia-resistant organism under hypoxic conditions sufficient to permit the organism to enter stasis;

b) incubating the first organism with a candidate compound;

c) observing the first organism for viability; and

d) comparing the first organism'"'"'s viability against a second anoxia-resistant organism'"'"'s viability incubated under normoxic conditions in the presence of the candidate compound,

wherein viability of the second organism and lack of viability of the first organism identifies the candidate compound as an anti-tumor compound.

30. The method of claim 29, wherein the hypoxic conditions have less than 10% oxygen.

31. The method of claim 30, wherein the hypoxic conditions are anoxic.

32. The method of claim 29, further comprising removing the candidate compound from the first and second organisms.

33. The method of claim 29, wherein observing the first organism for viability comprises observing them for movement.

34. The method of claim 29, wherein the first and second anoxia-resistant organisms are nematodes.

35. The method of claim 34, wherein the nematode is Caenorabditis elegans.

36. The method of claim 29, wherein the first and second anoxia-resistant organisms are vertebrate organisms.

37. The method of claim 36, wherein the vertebrate organisms are embryos.

38. The method of claim 37, wherein the embryos are Danio rerio.

39. The method of claim 29, wherein the organisms are in a hypoxic environment for at least 30 minutes.

40. The method of claim 39, wherein the organisms are in a hypoxic environment for at least 1 hour.

41. The method of claim 40, wherein the organisms are in a hypoxic environment for at least 2 hours.

42. An antitumor composition comprising an antitumor compound identified by a process comprising:

a) incubating a first anoxia-resistant organism under hypoxic conditions sufficient to induce stasis;

b) incubating the first organism with a candidate compound; and

c) comparing the first organism'"'"'s viability against a second anoxia-resistant organism'"'"'s viability incubated under normoxic conditions in the presence of the candidate compound,

wherein the compound is an antitumor compound if the first anoxia-resistant organism is no longer viable and the second anoxia-resistant organism is viable after incubation with the candidate compound.

43. The composition of claim 42, wherein the first and second anoxia-resistant organisms are nematodes.

44. The composition of claim 42, wherein the first and second anoxia-resistant organisms are embryos.

45. The composition of claim 44, wherein the first and second anoxia-resistant organisms are vertebrate embryos.

46. The composition of claim 42, wherein the hypoxic conditions are less than 10% oxygen.

47. The composition of claim 46, wherein the hypoxic conditions are anoxic.

48. The composition of claim 47, wherein the first organism is incubated under hypoxic conditions for more than 30 minutes.

49. The composition of claim 48, wherein the first organism is incubated under hypoxic conditions for more than 1 hour.

50. The composition of claim 42, wherein the candidate compound is a small molecule.

51. The composition of claim 42, wherein the anti-tumor compound comprises mitotracker red.

52. A method for killing cancer cells in a patient with a tumor comprising administering to the patient an therapeutically effective amount of an antitumor compound identified by the process comprising:

a) incubating a first anoxia-resistant organism under hypoxic conditions sufficient to permit the organism to enter stasis;

b) incubating the first organism with a candidate compound;

c) observing the first organism for viability; and

d) comparing the first organism'"'"'s viability against a second anoxia-resistant organism'"'"'s viability incubated under normoxic conditions in the presence of the candidate compound,

wherein viability of the second organism and lack of viability of the first organism identifies the candidate compound as an anti-tumor compound.

53. The method of claim 52, wherein the compound is administered directly to the tumor.

54. The method of claim 53, wherein the compound is injected into the tumor.

55. The method of claim 52, further comprising administering to the patient chemotherapy, radiotherapy, immunotherapy, or gene therapy.

56. The method of claim 52, further comprising resecting at least a portion of the tumor from the patient.

57. The method of claim 52, wherein the compound is mitotracker red.

58. A method for screening for a compound that induces stasis in biological material comprising:

a) incubating a first organism capable of stasis with a candidate compound; and

b) evaluating the first organism for stasis,

wherein the compound is a stasis inducer if the first organism exhibits stasis after exposure to the compound.

59. The method of claim 58, further comprising

c) comparing the ability to enter stasis in the first organism with a second organism not incubated or no longer incubated with the candidate compound.

60. The method of claim 58, further comprising

d) removing the compound from the first organism;

and

e) evaluating the first organism for loss of stasis,

wherein the compound is a reversible stasis inducer if the first organism exhibits stasis after incubation with the compound, but no longer exhibits stasis after the compound is removed.

61. A method of screening for a compound that improves the ability to undergo stasis comprising:

a) incubating a first organism capable of undergoing stasis under hypoxic conditions;

b) exposing the first organism to a candidate compound;

c) incubating a second organism capable of undergoing stasis under the same hypoxic conditions as the first organism;

d) comparing the first organism and the second organism.

62. A stasis inducer compound identified by a process comprising:

a) incubating an organism capable of entering stasis with a candidate compound; and

b) evaluating the organism for stasis,

wherein the compound is a stasis inducer if the organism exhibits stasis after incubation with the compound.

63. A reversible stasis inducer compound identified by a process comprising:

a) incubating an organism capable of entering stasis with a candidate compound;

b) comparing the organism with an organism capable of entering stasis that is no longer incubated with the candidate compound,

wherein the compound is a stasis inducer if the organism exhibits stasis after incubation with the compound, but does not exhibit stasis when no longer incubated with the compound.

64. The reversible stasis inducer compound of claim 63, wherein the organism no longer exposed to the candidate compound in c) is the organism of a).

65. A method of inducing stasis in biological material comprising administering to the biological material a stasis inducer compound.

66. The method of claim 65, further comprising lowering the temperature of the biological material.

67. The method of claim 65, wherein the biological material is an organ.

68. The method of claim 65, wherein the biological material is tissue.

69. The method of claim 65, wherein the biological material is an organism.

70. The method of claim 69, wherein the organism is a vertebrate organism.

71. The method of claim 70, wherein the vertebrate organism is an embryo.

72. The method of claim 70, wherein the vertebrate organism is a mammal.

73. The method of claim 72, wherein the mammal is a human.

74. A method of inducing stasis in a cell of an organism comprising administering to the cell of the organism an effective amount of a stasis inducer compound identified by a process comprising:

a) incubating an organism capable of entering stasis with a candidate compound;

b) evaluating the organism for loss of stasis after the compound is removed,

wherein the compound is a stasis inducer if the organism exhibits stasis after incubation with the compound, but no longer exhibits stasis after the compound is removed.

75. A method of inducing stasis in an organism comprising administering to the organism an effective amount of a stasis inducer compound identified by a process comprising:

a) incubating an organism capable of entering stasis with a candidate compound;

b) evaluating the organism for loss of stasis after the compound is removed,

wherein the compound is a stasis inducer if the organism exhibits stasis after incubation with the compound, but no longer exhibits stasis after the compound is removed.

76. A method of identifying a modulator of stasis in a biological material undergoing stasis comprising:

a) incubating a first biological material undergoing stasis with a candidate compound, wherein the first biological material is incubated under hypoxic conditions;

b) evaluating the first biological material for loss of stasis;

c) comparing the first biological material with a second biological material undergoing stasis but not incubated with the candidate compound, wherein a difference in stasis between the first and second biological materials identifies the compound as a candidate modulator of stasis.